Please assess the completion status of the following clinical trial:

Trial Title: 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* 18 to 82 years of age, inclusive~* Chronic Kidney Disease with a GFR category of G3a-G5 and not yet on dialysis~* eGFR ≥ 10 and ≤ 65 mL/minute/1.73 m2~* Anemia secondary to CKD with an ESA status and a Screening HGB as per protocol~* Iron replete with ferritin and TSAT levels as defined per protocol~Key Exclusion Criteria:~* BMI \> 44.0 kg/m2~* Red blood cell transfusion within 11 weeks prior to the Screening visit~* Androgen therapy within the previous 21 days prior to the Screening visit~* Intravenous iron within the past 4 weeks prior to the Screening visit~* AST or ALT \>1.8x ULN, alkaline phosphatase \>2x ULN, or total bilirubin \>1.5x ULN~* Screening ECG with QTc \> 500 msec~* Uncontrolled hypertension~* Class III or IV congestive heart failure~* Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to the Screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 82 Years
- Healthy Volunteers: f

Study Arms:
- AKB-6548 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).